Pathology consultation on HbA1c methods and interferences

American Journal of Clinical Pathology

Volumn 141, Issue 1, 2014, Pages 5-16

  Rhea, Jeanne M ^a   Molinaro, Ross ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood glucose concentrations; Diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HEMOGLOBIN C; HEMOGLOBIN D; HEMOGLOBIN E; HEMOGLOBIN S; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HEMOGLOBIN VARIANT;

ADULT; BETA THALASSEMIA; BLOOD PRESSURE; CAPILLARY ELECTROPHORESIS; CASE REPORT; CLINICAL EXAMINATION; FAMILY HISTORY; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; IMMUNOASSAY; IMPAIRED GLUCOSE TOLERANCE; ION EXCHANGE; LABORATORY TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL EXAMINATION; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; WORKPLACE; AFFINITY CHROMATOGRAPHY; BLOOD GLUCOSE CONCENTRATIONS; DIABETES MELLITUS; ERYTHROCYTE LIFESPAN; GENETICS; HBA1C INTERFERENCES; HBA1C INTERPRETATION; HBA1C METHODS; ION EXCHANGE CHROMATOGRAPHY; METHODOLOGY; BETA-THALASSEMIA; PROCEDURES;

BLOOD GLUCOSE CONCENTRATIONS; DIABETES; HBA1C INTERFERENCES; HBA1C INTERPRETATION; HBA1C METHODS;

ADULT; BETA-THALASSEMIA; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, ION EXCHANGE; DIABETES MELLITUS; ELECTROPHORESIS, CAPILLARY; ERYTHROCYTE AGING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HEMOGLOBIN, SICKLE; HEMOGLOBINS, ABNORMAL; HUMANS; IMMUNOASSAY; PREVALENCE;

EID: 84894465877     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPQ23GTTMLAEVL     Document Type: Review

References (63)

1. American Diabetes Association. Standards of medical care in diabetes: 2013. Diabetes Care. 2013;36(suppl 1):S11-S66.
2. Molinaro RJ. Targeting HbA1c: standardization and clinical laboratory measurement. MLO Med Lab Obs. 2008;40:10-19.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
5. Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31:1473-1478.
6. NGSP. HbA1c and estimated average glucose (eAG). Available at: www.ngsp.org/A1ceAG.asp. Accessed November 11, 2013.
7. 1c values when using assays incapable of detecting hemoglobin variants. Arch Pathol Lab Med. 2013;137:1788-1791.
8. Centers for Disease Control and Prevention. Sickle cell disease (SCD): data and statistics. Available at http://www.cdc.gov/ncbddd/sicklecell/data. html. Accessed December 2, 2013.
9. Marino BS, Fine KS. Pediatrics. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013.
10. McCurdy PR. 32-DFP and 51-Cr for measurement of red cell life span in abnormal hemoglobin syndromes. Blood. 1969;33:214-224.
11. Rhea JM, Roberts-Wilson TK, Molinaro RJ. Impact of hemoglobin variants on Hb Alc interpretation: do we assume too much? MLO Med Lab Obs. 2012;44:8-20.
12. Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet. 2012;379:373-383.
13. Taher AT, Musallam KM, Karimi M, et al. Contemporary approaches to treatment of beta-thalassemia intermedia. Blood Rev. 2012;26(suppl 1):S24-S27.
14. Shinar E, Rachmilewitz EA. Differences in the pathophysiology of hemolysis of α- and β-thalassemic red blood cells. Ann N Y Acad Sci. 1990;612:118-126.
15. Mirabile E, Testa R, Samperi P, et al. A mild form of Hb S-beta-thalassemia syndrome is assured in Sicilian patients by beta+mutant IVS-I nt 6(T→C). Eur J Haematol. 1997;58:67-69. (Pubitemid 27047135)
16. Centers for Disease Control and Prevention. Health of black or African American non-Hispanic population. Available at http://www.cdc.gov/nchs/fastats/ black-health.htm. Accessed November 11, 2013.
17. Clinical key. Thalassemia. Available at https://www.clinicalkey.com/ topics/hematology/thalassemia.html. Accessed November 11, 2013.
18. Zhu Y, Williams LM. Falsely elevated hemoglobin A1c due to S-beta+-thalassemia interference in Bio-Rad Variant II Turbo HbA1c assay. Clin Chim Acta. 2009;409:18-20.
19. Mongia SK, Little RR, Rohlfing CL, et al. Effects of hemoglobin C and S traits on the results of 14 commercial glycated hemoglobin assays. Am J Clin Pathol. 2008;130:136-140.
20. Chang J, Hoke C, Ettinger B, et al. Evaluation and interference study of hemoglobin A1c measured by turbidimetric inhibition immunoassay. Am J Clin Pathol. 1998;109:274-278. (Pubitemid 28110568)
21. Lin CN, Emery TJ, Little RR, et al. Effects of hemoglobin C, D, E, and S traits on measurements of HbA1c by six methods. Clin Chim Acta. 2012;413:819-821.
22. 2 [X-N-Met-1(NA1)Val→Glu]: a new β-chain abnormal hemoglobin observed in a Qatari female. Biochim Biophys Acta. 1985;831:257-260.
23. Roberts WL, Safar-Pour S, De BK, et al. Effects of hemoglobin C and S traits on glycohemoglobin measurements by eleven methods. Clin Chem. 2005;51:776-778. (Pubitemid 40463930)
24. 1c) by 23 methods. Clin Chem. 2008;54:1277-1282.
25. Food and Drug Administration 501 (k) Premarket notification. 2013. Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm. Accessed November 11, 2013.
26. Little RR, Roberts WL. A review of variant hemoglobins interfering with hemoglobin A1c measurement. J Diabetes Sci Technol. 2009;3:446-451.
27. A database of human hemoglobin variants and thalassemias. Available at http://globin.bx.psu.edu/hbvar/menu.html. Accessed November 11, 2013.
28. Moradkhani K, Henthom J, Riou J, et al. Hb Niigata [β1(NA1) Val→Leu] in a Romanian individual resulting from another nucleotide substitution than that found in the Japanese. Hemoglobin. 2007;31:477-482. (Pubitemid 350125640)
29. Shah SC, Malone JI, Boissel JP, et al. Hemoglobin South Florida: new variant with normal electrophoretic pattern mistaken for glycosylated hemoglobin. Diabetes. 1986;35:1073-1076. (Pubitemid 17176947)
30. Tan JA, Tan KL, Omar KZ, et al. Interaction of Hb South Florida (codon 1; GTG→ATG) and HbE, with β-thalassemia (IVS1-1; G→A): expression of different clinical phenotypes. Eur J Pediatr. 2009;168:1049-1054.
31. Fisher C, Hanslip J, Green BN, et al. Hb Watford [beta1(NA1)Val→Gly] : a new, clinically silent hemoglobin variant in linkage with a new neutral mutation. Hemoglobin. 2000;24:347-353.
32. Harano T, Harano K, Ueda S, et al. Hb Fukuoka [beta 2(NA2)His→Tyr]: a new mutation at the 2.3-diphosphoglycerate binding site. Hemoglobin. 1990;14:199-205. (Pubitemid 20256350)
33. Galdies R, Cassar W, Pizzuto M, et al. Hb Valletta [β-87(F3) Thr→Pro] and Hb Marseille/Long Island [β-2(NA2) His→Pro: (-1)Met-(+1)Val-(+2)Pro-Leu], in a unique compound heterozygote with a normal hemoglobin phenotype. Hemoglobin. 2010;34:169-174.
34. Schnedl WJ, Reisinger EC, Pieber TR, et al. Haemoglobin Graz, a novel haemoglobin variant. Diabetologia. 1995;38:122.
35. Labossiere A, Vella F, Hiebert J, et al. Hemoglobin Deer Lodge: 2 2 2 His leads to Arg. Clin Biochem. 1972;5:46-50.
36. Harano T, Harano K, Shibata S, et al. Hemoglobin Okayama [beta 2 (NA 2) His replaced by Gln]: a new 'silent' hemoglobin variant with substituted amino acid residue at the 2,3-diphosphoglycerate binding site. FEBS Lett. 1983;156:20-22. (Pubitemid 13058516)
37. Saisho Y, Saitoh F, Tabata M, et al. Two cases in which an abnormal hemoglobin (Hb Kamakura) was identified on the basis of an abnormally low glycohemoglobin levels. Intern Med. 2003;42:595-598. (Pubitemid 36926837)
38. 2 4(A1)Thr→Asn), a new electrophoretically silent variant, by mass spectrometry and molecular modeling studies. J Chromatogr A. 2006;1115:118-124.
39. 25(A2)Pro→Ala], an electrophoretically silent variant with impaired glycation. Clin Chem. 2003;49:137-143.
40. Langdown JV, Williamson D, Beresford CH, et al. A new beta chain variant, Hb Tyne [beta 5(A2)Pro→Ser]. Hemogbbin. 1994;18:333-336.
41. Wilson CI, Cave RJ, Lehmann H, et al. Haemoglobin Warwickshire (β5 [A2] Pro→Arg): a possible 'fine tuning' of 2.3-DPG affinity by β5 Pro. FEBS Lett. 1984;176:331-333. (Pubitemid 15208270)
42. Joly P, Garcia C, Lacan P, et al. Two new hemoglobin variants: Hb Aix-Les-Bains [β5(A2)Pro→Leu; HBB:c.17 C>T] and Hb Dubai [α122(H5)His→Leu (α2); HBA2:c.368 A>T]. Hemogbbin. 2011;35:147-151.
43. Bachir D, Galacteros F. Hemoglobin C. Orphanet Encycbpedia. 2004. Available at https://www.orpha.net/data/patho/GB/uk-HbC.pdf. Accessed November 11, 2013.
44. Harano T, Harano K, Ueda S, et al. Hemoglobin Machida [beta 6 (A3) Glu replaced by Gln]: a new abnormal hemoglobin discovered in a Japanese family: structure, function and biosynthesis. Hemoglobin. 1982;6:531-535. (Pubitemid 13242343)
45. Blackwell RQ, Liu CS, Wang CL. Haemoglobin Siriraj, -7 (A4) Glu leads to Lys, in a Chinese subject in Taiwan. Vox Sang. 1972;23:433-438.
46. Edison ES, Sathya M, Rajkumar SV, et al. A novel β-globin gene mutation HBB.c.22 G>C produces a hemoglobin variant (Hb Vellore) mimicking HbS in HPLC. Int J Lab Hematol. 2012;34:556-558.
47. 1c). Hemoglobin. 2009;33:137-142.
48. Lena-Russo D, Orsini A, Vovan L, et al. Hb N-Timone [alpha 2 beta 2(8)(A5)Lys→Glu]: a new fast-moving variant with normal stability and oxygen affinity. Hemogbbin. 1989;13:743-747. (Pubitemid 20095930)
49. Moo-Penn WF, Johnson MH, McGuffey JE, et al. Hemoglobin Rio Grande [beta 8 (A5) Lys leads to Thr] a new variant found in a Mexican-American family. Hemoglobin. 1983;7:91-95. (Pubitemid 13113674)
50. Agarwal S, Hattori Y, Gupta UR, et al. A novel Indian β-thalassemia mutation: Hb Lucknow [beta8(A5)Lys→Arg]]. Hemoglobin. 1999;23:263-265.
51. Harano K, Harano T, Koide G, et al. Hb Nakano [β8(Lys→Met]: a new β chain variant found in a Japanese woman. Hemoglobin. 1995;19:397-401.
52. Kyrri A, Felekis X, Kalogerou E, et al. Hb Limassol [beta8(A5) Lys→Asn]: a new hemoglobin variant. Hemoglobin. 2001;25:421-424. (Pubitemid 34037657)
53. Lacan P, Moreau M, Becchi M, et al. Two new hemoglobin variants: Hb Brem-sur-Mer [beta9(A6)Ser→Tyr] and Hb Passy [alpha81(F2)Ser→Pro (alpha2)]. Hemoglobin. 2005;29:69-75.
54. Cataldo MJ, Bonini-Domingos AC, Bonini-Domingos CR. Heterozygosis for hemoglobin Porto Alegre identified by a combination of laboratory diagnostic methodologies. Rev Bras Hematol Hemoter. 2012;34:305-306.
55. 1c by routine cation exchange high performance liquid chromatography. Hemoglobin. 2009;33:45-50.
56. Hidaka K, Iuchi I, Shimasaki S, et al. The survey of abnormal hemoglobins in the Kobe district: Hb G-Coushatta [beta 22(B4)Glu→Ala], Hb Ankara (beta 10(A7)Ala→Asp], Hb Handa [alpha 90(FG2)Lys→Met], and Hb J-Habana [alpha 71(E20)Ala→Glu]. Hemoglobin. 1986;10:65-72. (Pubitemid 16131319)
57. Krishnan K, Martinez F, Wille RT, et al. Hb Washtenaw [beta 11(A8)Val→Phe]: an electrophoretically silent, unstable, low oxygen affinity variant associated with anemia and chronic cyanosis. Hemoglobin. 1994;18:285-295. (Pubitemid 24282003)
58. Gilbert AT, Fleming PJ, Sumner DR, et al. Hemoglobin Windsor or beta 11 (A8)Val→Asp: a new unstable beta-chain hemoglobin variant producing a hemolytic anemia. Hemoglobin. 1989;13:437-453. (Pubitemid 19256521)
59. Djoumessi S, Rousseaux J, Dautrevaux M. Structural studies of a new hemoglobin: HbJ lens, beta 13 (A10) Ala leads to Asp. FEBS Lett. 1981;136:145-147. (Pubitemid 12133492)
60. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem. 2001;47:153-163. (Pubitemid 32142912)
61. 1c determinations evaluated. Clin Chem. 1997;43:644-648.
62. 1c analysis - common practices in clinical laboratories. Clin Chim Acta. 2009;406:124-128.
63. Behan KJ, Merschen J. HbA1c does not always estimate average glucose. Clin Lab Sci. 2011;24:71-77.